

Amendments to the Specification

The following paragraph was added by entry of the Preliminary Amendment filed on June 26, 2001, and is further amended as follows:

B₁
This is a continuation of U.S. Patent Appl. No. 09/227,081, filed January 5, 1999, now U.S. Patent No. 6,375,950, which is a divisional of U.S. Patent Appl. No. 08/906,332, filed August 5, 1997, now U.S. Patent No. 5,902,585, further which is a divisional of U.S. Patent Appl. No. 08/234,987, filed April 25, 1994, now U.S. Patent No. 5,683,693, the contents of which are incorporated herein by reference in their entirety.

Please amend the paragraph beginning on page 9, line 11, as follows:

B₂
Preferred allogeneic or xenogeneic cells for inducing T cell tolerance are lymphoid cells, for example peripheral blood lymphocytes or splenic cells. Preferred lymphoid cells for inducing T cell tolerance are B cells. B cells can be purified from a mixed population of cells (e.g., other cell types in peripheral blood or spleen) by standard cell separation techniques. For example, adherent cells can be removed by culturing spleen cells on plastic dishes and recovering the non-adherent cell population. T cell can be removed from a mixed population of cells by treatment with an anti-T cell antibody (e.g., anti-Thy1.1 and/or antiThy1.2) and complement. In one embodiment, resting lymphoid cells, preferably resting B cells, can be isolated by techniques known in the art, for example based upon their small size and density. Resting lymphoid cells can be isolated for example by counterflow centrifugal elutriation as described in Example 1. Using counterflow centrifugal elutriation, a small, resting lymphoid cell population depleted of cells which can activate T cell responses can be obtained by collecting a fraction(s) at 14-19 ml/min., preferably 19 ml/min. (at 3,200 rpm). Alternatively, small, resting lymphocytes (e.g., B cells) can be isolated by discontinuous density gradient centrifugation, for example using a ~~Ficoll or Percoll gradient~~ FICOLL® gradient (Pharmacia Biotech AB Corporation of Upsala, Sweden) or a PERCOLL® gradient (Amersham Pharmacia Biotech AB Corporation of Upsala, Sweden), and a layer containing small, resting lymphocytes can be obtained after centrifugation. Small resting B cells can also be distinguished from activated B cells by assaying for expression of costimulatory molecules, such as B7-1 and/or B7-2, on the surface of activated B cells by standard techniques (e.g., immunofluorescence).

Please insert the following paragraph beginning at page 18, line 36:

B₃
--The hybridoma identified in this application as MR1 was deposited on May 22, 1992 with the American Type Culture Collection, P.O. Box 1549, Manassas, Virginia, 20108, in compliance with the Budapest Treaty, and accorded Accession Number ATCC HB 11048. All restrictions as to the availability to the public of the hybridoma cell line MR1 will be irrevocably withdrawn upon issuance of a United States Patent to this application. Also, access to the MR1 cell line will be available to the Commissioner during the pendency of this patent application or to one determined by the Commissioner to be entitled to such cell line under 37 C.F.R. §1.14 and 35 U.S.C. §122.--